Plain-English translation of NCT07657793 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication that affects the immune system, can help treat a serious complication of lupus called immune thrombocytopenia—a condition where the body destroys its own platelets, which help blood clot. You would take this medication alongside your regular lupus medicines for up to 48 weeks. The study wants to know if the medication can raise platelet counts and whether it's safe to use long-term.
Some people with lupus develop severely low platelet counts that don't respond well to standard treatments like corticosteroids. Researchers believe this medication might work differently to help control the immune system and protect platelets, offering hope for patients who aren't getting better with current options.
You likely qualify if…
You likely don't qualify if…
For the first 24 weeks, you'll take either the new medication or a placebo pill once daily, along with your regular lupus medicines. Then for another 24 weeks, everyone receives the actual medication to see how well it works long-term. You'll have in-person clinic visits at several timepoints (including baseline, week 4, 12, 24, 28, 36, and 48) for blood tests and check-ups, plus shorter phone calls between visits to report how you're doing and check your platelet counts.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
China